Antithrombotic agent’s effects in thrombotic events caused by Covid-19: A systematic review

Abstract

Introduction: The association of dipyrone with agranulocytosis has a variable incidence in different studies. The geographic variety, with risk proportions between 0.8 and 23.7, it can be explained by differences in patterns of use, doses, and concomitant use of other drugs. Methodology: Based on this variation of protocols on the use and release of dipyrone, this paper is a study carried out through a literature review, adding data, studies and research related to dipyrone and the association with cases of agranulocytosis, guiding the reasons why is prohibited, or released only by medical prescription in some countries, and unrestricted in others. Results and discussion: Considering the over-used of metamizole by the brazilian, a higher frequency of cases of agranulocytosis was expected, but this has not been the case. due to the undeniable effectiveness of dipyrone as analgesic and antipyretic, its adverse effects are lower compared to other drugs of the same class, such as paracetamol; In 2010, the Federal Public Ministry requested that dipyrone-based drugs be dispensed with a medical prescription, because their adverse effects, however the request was rejected by ANVISA, who claimed that: the incidence of side effects are low and the benefits of the drug outweigh the risks. Considerations: Based on the studies is noticeable the need for more research, with different populations, ethnicities and ages, aiming at reliable and decisive results for the continuity and/or return of the commercialization and safe supply of metamizole.